Representing a Life Science Company with Global Licensing Agreement with a Major Generic Pharmaceutical Company
Our client is a life sciences company based in Fort Collins, CO and New York, NY. We assisted the client with negotiating world-wide exclusive licensing rights for a product from a well-known publicly traded generic pharmaceutical company with its U.S. headquarter in Princeton, NJ. The deal value could exceed $100 million based on certain benchmarks in the agreement.
We helped the client achieve three major milestones: 1) obtained world-wide exclusive licensing rights, with no upfront capital. The upfront capital was deferred for 18 months from the execution date; 2) negotiated favorable terms that if our client goes public, client has the right to pay the licensor up-front cash or shares worth the initial payment; and 3) negotiated protection mechanism in case of termination that were unfavorable to our client.
Tannenbaum Helpern helped the client think “outside the box” to achieve its goals and some of the negotiated terms were not typically included in these types of licensing rights transactions. The client was extremely happy with the result and with how we negotiated the transaction, particular when the other party is a major generic pharmaceutical company experienced with such deal negotiations.